Status:

COMPLETED

The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

Lead Sponsor:

Brendan Barrett

Collaborating Sponsors:

Nova Scotia Health Authority

Hopital Charles Lemoyne

Conditions:

Chronic Kidney Disease

Eligibility:

All Genders

40-75 years

Phase:

NA

Brief Summary

Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat. Treatments a...

Detailed Description

The pilot study is designed in two phases. The first phase is intended to provide data on some key points that need to be addressed prior to future funding applications to the CIHR and the NHLBI. Thes...

Eligibility Criteria

Inclusion

  • Stratum 1 (expected about 50% of trial subjects): Diabetes mellitus (by clinical history with documented prior plasma glucose levels in the diabetic range, or on hypoglycemic medications) and CKD as documented by calculated (Cockroft-Gault equation) creatinine clearance between 25 and 60 mls/min/1.73m2 derived from the screening serum creatinine value and the next most recent known value from more than 2 weeks prior; OR
  • Stratum 2 (expected about 20% of trial subjects): Non-diabetic with CKD as defined for Stratum 1 and proteinuria of \> 1g/L by dipstick in random urine at screening; OR
  • Stratum 3 (expected about 30% of trial subjects): Non-diabetic with CKD as defined for stratum 1, but without proteinuria as for stratum 2 at screening

Exclusion

  • Unwilling to provide informed consent
  • Likely to die of any known existing disease within 6 months
  • Recently unstable/advanced cardiovascular disease (MI or acute coronary syndrome, hospitalized heart failure, TIA or stroke, leg amputation or gangrene in past 6 months)
  • Currently receiving active treatment for a malignant, neoplastic disease other than localized non-melanoma skin cancer
  • Progressive kidney disease currently treated by immunotherapy
  • Currently receiving dialysis or likely to do so within 6 months
  • Current organ transplant recipient (or planned within 6 months)
  • Currently receiving ongoing care for CKD, or cardiovascular disease, in a multiple intervention, disease management program.
  • Currently enrolled in another interventional trial
  • Residing in a location not amenable to follow up for the trial

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

474 Patients enrolled

Trial Details

Trial ID

NCT00231803

Start Date

April 1 2005

End Date

June 1 2008

Last Update

May 13 2022

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

St. Paul's Hospital

Vancouver, British Columbia, Canada, V6Z 1Y6

2

Memorial University of Newfoundland

St. John's, Newfoundland and Labrador, Canada, A1B 3V6

3

Capitol District Health Authority

Halifax, Nova Scotia, Canada, B3H 1V8

4

London Health Sciences Centre

London, Ontario, Canada, N6A 4G3